December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Greenwich LifeSciences, Inc. - Common stock (NQ:GLSI)

9.068 +0.268 (+3.04%)
Streaming Delayed Price Updated: 9:51 AM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Greenwich LifeSciences, Inc. - Common stock

< Previous 1 2 Next >
News headline image
Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)
From Glancy Prongay & Murray LLP
Via Business Wire
Greenwich LifeSciences Inc. (NASDAQ: GLSI) Near the Top of Equities by Percentage Gain on 2/14
Via Investor Brand Network
News headline image
Greenwich LifeSciences Provides Year End Update
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Financing Strategy & Corporate Update
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Announces Suspension of Share Repurchase Program
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Resume Stock Repurchase Program
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.